11/20
10:14 am
srrk
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug [Yahoo! Finance]
Low
Report
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug [Yahoo! Finance]
11/15
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
02:14 am
srrk
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
12:36 pm
srrk
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at HC Wainwright from $35.00 to $40.00. They now have a "buy" rating on the stock.
11/12
07:30 am
srrk
Scholar Rock GAAP EPS of -$0.66 misses by $0.06 Nov. 12, 2024 7:28 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
Medium
Report
Scholar Rock GAAP EPS of -$0.66 misses by $0.06 Nov. 12, 2024 7:28 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
11/12
07:00 am
srrk
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
Medium
Report
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
11/11
07:23 am
srrk
Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Medium
Report
Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/4
10:47 pm
srrk
Scholar Rock Holding Co. (NASDAQ: SRRK) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
Medium
Report
Scholar Rock Holding Co. (NASDAQ: SRRK) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
11/4
08:00 am
srrk
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
Medium
Report
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
11/1
08:00 am
srrk
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Medium
Report
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
10/31
08:35 pm
srrk
Scholar Rock to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Scholar Rock to Participate in Upcoming Investor Conferences [Yahoo! Finance]
10/31
04:00 pm
srrk
Scholar Rock to Participate in Upcoming Investor Conferences
Low
Report
Scholar Rock to Participate in Upcoming Investor Conferences
10/31
08:00 am
srrk
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Medium
Report
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
10/22
08:00 am
srrk
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
Medium
Report
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
10/21
11:44 am
srrk
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? [Yahoo! Finance]
Low
Report
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? [Yahoo! Finance]
10/18
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/15
08:55 am
srrk
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
Low
Report
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
10/14
11:16 am
srrk
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $31.00. They now have an "overweight" rating on the stock.
Low
Report
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $31.00. They now have an "overweight" rating on the stock.
10/11
12:46 pm
srrk
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at BMO Capital Markets from $34.00 to $38.00. They now have an "outperform" rating on the stock.
Low
Report
Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at BMO Capital Markets from $34.00 to $38.00. They now have an "outperform" rating on the stock.
10/9
05:52 am
srrk
Here's Why Everybody's Talking About Scholar Rock Right Now [Yahoo! Finance]
Medium
Report
Here's Why Everybody's Talking About Scholar Rock Right Now [Yahoo! Finance]
10/9
01:31 am
srrk
Scholar Rock prices $300M stocks and warrants [Seeking Alpha]
Medium
Report
Scholar Rock prices $300M stocks and warrants [Seeking Alpha]
10/8
11:13 pm
srrk
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
10/8
11:08 pm
srrk
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
10/8
12:40 pm
srrk
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal [Yahoo! Finance]
Medium
Report
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal [Yahoo! Finance]
10/8
08:36 am
srrk
Scholar Rock Holding Corporation [Yahoo! Finance]
High
Report
Scholar Rock Holding Corporation [Yahoo! Finance]